Acetylcholine Receptor Modulating Antibody
0099521
Ordering Recommendation
Assessment of clinical activity of and initial diagnostic testing for myasthenia gravis. For reflexive panel, which contains binding, blocking, and modulating antibodies, refer to Acetylcholine Receptor Antibody Reflexive Panel  (2001571).
Mnemonic
ACHRMOD
Methodology
Semi-Quantitative Flow Cytometry
Performed
Sun-Fri
Reported
2-7 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Serum separator tube.  
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 0.5 mL serum to an ARUP Standard Transport Tube. (Min: 0.3 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Contaminated, hemolyzed, or severely lipemic specimens.  
Remarks
  
Stability
After separation from cells: Ambient: 2 hours; Refrigerated: 2 weeks; Frozen: 1 year  (avoid repeated freeze/thaw cycles)  
Reference Interval
Negative: 0-45% modulating
Positive: 46% or greater modulating

Effective August 20, 2012  
Interpretive Data
Approximately 85-90 percent of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibodies. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair binding of acetylcholine to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10-15 percent of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibodies.

See Compliance Statement B: www.aruplab.com/CS
Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
 
Note
 
CPT Code(s)
83516
Components
Component Test Code*Component Chart Name
0099521Acetylcholine Modulating Antibody
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • AChR Antibody
  • ACHR modulating antibody
  • Muscle nicotinic Acetylcholine Receptor (AChR) Modulating Antibody
  • Myasthenia Gravis Antibodies